retatrutide type 2 diabetes trial nct Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA What is the pipeline for

Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming

Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney Disease: a Systematic Review and Meta-Analysis

The primary reasons for exclusion were as follows: (1) concomitant use of ramelteon, suvorexant, lemborexant, hydroxyzine, trazodone, mianserin, and/or antipsychotics (34.9% for hydroxyzine and 44.6% for haloperidol), (2) simultaneous administration of hydroxyzine and haloperidol (20.2% for hydroxyzine and 18.7% for haloperidol), and (3) single administration of hydroxyzine or haloperidol for only 1 day, not for 2 or more consecutive days (8.3% for hydroxyzine and 10.7% for haloperidol), in that order

--1 has been certified by multiple national authorities

According to a 2024 report by the trade body UK Pet Food, 50% of dogs and 43% of cats are overweight

These fast-absorbing sublingual tablets are your perfect weight loss ally